Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sandu Pharmaceuticals Ltd has reached a new 52-week low of Rs.35.11, marking a significant decline amid broader market pressures and company-specific performance issues. The stock has underperformed its sector and benchmark indices, reflecting ongoing challenges in growth and profitability metrics.

Sandu Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.35.8 on 21 Jan 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting persistent challenges in its financial and market performance.

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 December 2025, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.36.76, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector.

Sandu Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. This shift follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, underscoring the complexities faced by the stock in recent periods.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid broader market activity. The stock’s performance contrasts with the overall positive trend in the Sensex, highlighting ongoing challenges within the company’s financial and operational metrics.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals touched a fresh 52-week low of Rs.37.21 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.21 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock has experienced a notable downward trend over the past three days, reflecting ongoing challenges within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.38, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and benchmark indices, reflecting persistent challenges in its financial performance and market positioning.

Sandu Pharmaceuticals has hit a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and experienced a notable drop over the past year. Financial metrics indicate challenges, including low Return on Equity and concerns regarding debt management.

Sandu Pharmaceuticals has hit a new 52-week low, reflecting ongoing challenges in its market performance. The company has seen a notable decline over the past year, underperforming compared to broader market indices. Financial metrics indicate weak long-term fundamentals and limited capacity to service its debt.

Sandu Pharmaceuticals has hit a new 52-week low, reflecting ongoing challenges in the Pharmaceuticals & Biotechnology sector. The company has consistently underperformed market benchmarks, with a one-year return significantly lower than the Sensex. Weak financial metrics, including low ROE and modest sales growth, further highlight its struggles.

Sandu Pharmaceuticals has hit a new 52-week low, reflecting a significant decline in its stock price over the past year. The company has consistently underperformed against market benchmarks and faces challenges in financial strength, with weak metrics in return on equity and debt servicing capabilities.